Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 1;109(8):2711-2715.
doi: 10.3324/haematol.2024.284976.

Acute myeloid leukemia with mast cell differentiation is characterized by interstitial mast cells, complex karyotype, TP53 alterations and poor prognosis

Affiliations

Acute myeloid leukemia with mast cell differentiation is characterized by interstitial mast cells, complex karyotype, TP53 alterations and poor prognosis

Do Hwan Kim et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
A representative case of acute myeloid leukemia with mast cell differentiation. (A) Mast cells (MC) are positive for CD117 (bright), CD45 (dim), CD38, CD123, CD34 (partial/dim), and CD13 (partial), and are negative for HLA-DR, with low side scatter (SSC), consistent with immature MC. (B) Peripheral blood and (C and D) bone marrow (BM) aspirate smears reveal myeloblasts (red arrow heads) which are large, with irregular nuclear contour, fine chromatin, inconspicuous nucleoli, and a small amount of agranular cytoplasm. Metachromatic blasts (green arrow heads) have a small to moderate amount of cytoplasm containing a few metachromatic granules. Erythroid dysplasia is present in the background (black arrow). (E) BM biopsy shows a hypercellular marrow (approx. 100% cellularity) with markedly increased blasts. Immunohistochemical stains for (F) CD117 (strong) and (G) tryptase (weak) highlight scattered MC. (F) CD117 also stains the myeloblasts (dim). (B-D) Wright-Giemsa stain, x1000. (E) Hematoxylin-eosin stain, x400. Immunohistochemistry: (F) x400 and (G) x600. AML-MC: acute myeloid leukemia with mast cell differentiation.
Figure 2.
Figure 2.
The molecular and cytogenetic findings of acute myeloid leukemia with mast cell differentiation. (A) Oncoplot of gene mutations and status of karyotype and TP53 deletion. (B) Lollipop graph of TP53 mutations in acute myeloid leukemia with mast cell (AML-MC) differentiation. (Template from Uniprot).
Figure 3.
Figure 3.
The overall survival of patients with acute myeloid leukemia with mast cell differentiation. Overall survival (OS) in (A) all 21 patients with acute myeloid leukemia with mast cell (AML-MC) differentiation, (B) patients aged ≥65 years and <65 years, (C) patients with ≥5% MC and <5% MC, (D) patients with mutated and wild-type TP53, (E) patients with a complex karyotype and non-complex karyotype, and (F) patients with and without allogeneic stem cell transplant (SCT).

References

    1. Sperr WR, Drach J, Hauswirth AW, et al. . Myelomastocytic leukemia: evidence for the origin of mast cells from the leukemic clone and eradication by allogeneic stem cell transplantation. Clin Cancer Res. 2005;11(19 Pt 1):6787-6792. - PubMed
    1. Valent P, Spanblochl E, Bankl HC, et al. . Kit ligand/mast cell growth factor-independent differentiation of mast cells in myelodysplasia and chronic myeloid leukemic blast crisis. Blood. 1994;84(12):4322-4332. - PubMed
    1. Wimazal F, Sperr WR, Horny HP, et al. . Hyperfibrinolysis in a case of myelodysplastic syndrome with leukemic spread of mast cells. Am J Hematol. 1999;61(1):66-77. - PubMed
    1. Rich A, Sun J, Aldayel AS, et al. . Myelomastocytic leukemia with aberrant CD25 expression: case report and review of the literature. Clin Lymphoma Myeloma Leuk. 2014;14(5):e173-177. - PubMed
    1. Johnson RC, Savage NM, Chiang T, et al. . Hidden mastocytosis in acute myeloid leukemia with t(8;21)(q22;q22). Am J Clin Pathol. 2013;140(4):525-535. - PubMed

Publication types

Substances